LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
US9701627B2 · kind B2 · utility
0Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2015 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Jun 16, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/192
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds, and methods of using the same, are provided as therapies for the treatment leucine-rich repeat kinase-2 (LRRK2)-related disorders including, but not limited to, neurodegenerative and neuroinflammatory disorders, such as Parkinson's Disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.